

***In Vitro* Metabolism of Aflatoxin B₂ by Animal and Human Liver¹**

Bill D. Roebuck,² Wayne G. Siegel,³ and Gerald N. Wogan⁴

Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139

ABSTRACT

The metabolism of aflatoxin B₂ by postmitochondrial supernatant fractions of duck, rat, mouse, and human livers was studied in an *in vitro* system. Duck liver had a much higher level of activity than had tissues from other species. Postmitochondrial supernatant equivalent to 0.2 g whole liver metabolized 40 to 80% of the initial substrate in 30 min, compared to < 6% for the other species. Among several metabolites formed by duck liver, aflatoxin B₁ was produced in amounts equivalent to 2 to 8% of the initial substrate, and metabolites having chromatographic properties postulated for aflatoxins 1 and 2 and aflatoxins M₁ and M₂ were also formed in small amounts. In contrast, rat, mouse, and human liver preparations produced no detectable aflatoxin B₁ and only small amounts of compounds thought to be aflatoxins Q₂ and P₂. The greater susceptibility of duck liver to the toxicity of aflatoxin B₂ may be attributable to its ability to form aflatoxin B₁, which could then be activated through further metabolism.

INTRODUCTION

We have been investigating the metabolism *in vitro* of aflatoxins by liver preparations from various experimental animals and from humans to provide information important for elucidation of mechanisms responsible for species differences in susceptibility to the toxic and carcinogenic actions of these compounds. Such information is relevant to pathways of metabolic activation and inactivation. Results of a previous study (11) of AFB₁⁵ metabolism have been reported previously; the present report deals with similar studies on AFB₂ (dihydro-AFB₁).

These results are of particular interest in connection with the mechanisms involved in metabolic activation of aflatoxins. Current evidence strongly supports the postulate that activation of AFB₁ occurs through the formation of the 2,3-epoxide, which may represent the ultimate carcinogenic derivative (5, 12). Activation of AFB₂ could not take place directly through the same pathways, since the latter compound lacks the 2,3-double bond. That activation of AFB₂ does not readily occur in rats was in fact indicated by our earlier findings (14, 15) that its potency in that species is

reduced by more than 150 times, compared to that of AFB₁. In contrast, AFB₂ is considerably more active in some other systems, including duck (in which its lethal potency is about one-fourth as great as that of AFB₁), chicken embryo, cell culture, and various subcellular biochemical model systems (13).

Therefore, it was of interest to determine the pathways through which AFB₂ was metabolized by duck liver, compared to those metabolized by rat, mouse, and human livers. Our results indicate that duck liver metabolizes AFB₂ much more actively than do the mammalian species and that a significant pathway in this transformation is 2,3-desaturation to form AFB₁. The latter compound would then be available for activation through the epoxidation pathway as in other species. We found no evidence for this transformation in rodent or human liver.

MATERIALS AND METHODS

Aflatoxins. Ring-labeled [¹⁴C]AFB₂ was purified by preparative scale TLC from chloroform extracts of *Aspergillus parasiticus* cultures incubated with [1-¹⁴C]acetate. Authentic samples of aflatoxins B₁, B₂, P₁, M₁, Q₁, and B_{2a} and aflatoxicol were available in our laboratory or provided by Dr. G. H. Büchi, Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Mass.

Radioactivity Measurements. A Packard Tri-Carb Model 2002 liquid scintillation spectrometer was used to measure radioactivity. [¹⁴C]Toluene standard was used for internal standardization. Chloroform-insoluble samples were counted in Aquasol scintillation fluid, and chloroform-soluble aflatoxins were counted in toluene-based scintillation fluid (4 g PPO and 100 mg POPOP per liter reagent-grade toluene). All phosphors and standards were products of New England Nuclear, Boston, Mass.

Tissues. Livers were immediately excised from males of 3 species killed by decapitation: 4- to 7-day-old Pekin ducks (C and R Duck Farm, Long Island, N. Y.), 28-day-old Fischer CDF rats (Charles River Breeding Laboratories, Inc., Wilmington, Mass.), and 31-day-old White Swiss CFW mice (Carworth Farms, New City, N. Y.). For each species, livers from 3 to 9 animals were pooled to provide sufficient material for all subsequent assays.

Samples of human liver (5 to 20 g each) were obtained from cadavers of renal transplant donors through the cooperation of Dr. A. B. Cosimi, Assistant in Surgery, Massachusetts General Hospital, Boston, Mass. Donors were maintained by artificial respiration for varying lengths of time after 2 successive inactive electroencephalograms at 24-hr intervals. Liver samples were removed when kidney transplantation was performed. Pertinent information on the 2 individuals involved can be summarized as follows. Subject 1 was a 49-year-old woman who died of a brain abscess, having been hospitalized for 12 days during which

¹ Financial support was provided by NIH Grants 5 PO1 ES 00597 and 5 TO1 ES 00056 and Contract NO1 CP 43265. Preliminary accounts of this work were presented at the 66th Meeting of the American Association for Cancer Research, Inc., May 7 to 11, 1975, San Diego, Calif. (10).

² Present address: Department of Pathology, Dartmouth Medical School, Hanover, N. H. 03755.

³ Present address: University of California at San Diego Medical School, San Diego, Calif. 92115.

⁴ To whom requests for reprints should be addressed, at Massachusetts Institute of Technology, Room 56-215, Cambridge, Mass. 02139.

⁵ The abbreviations used are: AFB₁, aflatoxin B₁; AFB₂, aflatoxin B₂; TLC, thin-layer chromatography; PMS, postmitochondrial supernatant.

Received September 12, 1977; accepted January 13, 1978.

she received massive antibiotic and steroid therapy. Histopathological examination revealed the presence of cirrhosis and lipid infiltration, associated probably with alcoholism. Subject 2 was a 38-year-old man who died of traumatic head injury and was maintained for 48 hr before a sample was obtained. Histopathological examination revealed milk lipid infiltration and fibrosis. Both subjects were Caucasian.

All excised liver samples were immediately placed in ice-cold potassium phosphate buffer (pH 7.4; 50 mM).

Subcellular Fractionation. Within 30 min after removal of the liver, a 25% homogenate was prepared in an all-glass Dounce homogenizer with 2.7 mM KCl:50 mM potassium phosphate buffer (pH 7.4). The PMS of a 20-min centrifugation at $9000 \times g$ was used in the *in vitro* studies. All procedures were performed at 0–4°.

In Vitro Metabolism of AFB₂. PMS aliquots equivalent to 0.2 g whole liver were incubated with [¹⁴C]AFB₂ (0.04 to 0.08 μCi) in a medium consisting of potassium phosphate buffer (pH 7.4; 50 mM):KCl (2.7 mM, glucose 6-phosphate (2.4 mM), NADP⁺ (0.1 mM), and MgCl₂ (1.0 mM). The total volume per flask was 5.0 ml (1, 3). After a 5-min incubation period to generate NADPH, approximately 50 μg AFB₂ in 0.05 ml reagent-grade methanol was added, initiating metabolism at a final AFB₂ concentration of approximately 30 μM. For Human 1 and Human 2 incubations, 130 μg and 207 μg AFB₂, respectively, were added as described above. These higher levels were added to facilitate the identification of AFB₁ as an intermediate. Absorbance values of aliquots of the methanolic AFB₂ solution at 362 nm provided an accurate measure of the actual quantity added (9). Duplicate flasks were shaken aerobically at 37° for 5, 10, 15, and 30 min. The results were compared to those obtained with AFB₂ incubated with PMS inactivated by heating at 100° for 10 min. The addition of 5 ml cold methanol terminated the incubations. The flasks were stored no longer than 48 hr at –20° before extraction.

Extraction of Aflatoxins from the Incubation Medium. The methanolic incubation medium was extracted 5 times successively with 25-ml aliquots of reagent-grade chloroform. The combined chloroform extracts (125 ml) were concentrated to 2 ml under vacuum at 40°. The chloroform-insoluble fraction was quantitatively recovered. This fraction included a clear supernatant phase and denatured cellular constituents. Aliquots of both fractions were taken for determination of radioactivity.

TLC. The chloroform-soluble aflatoxins were separated by TLC on 0.25-mm plates of Adsorbosil-1 (Applied Science Labs., Inc., State College, Pa.) in chloroform:acetone:water (88:12:1.5). For resolution of AFB₂ and aflatoxicol, which cochromatograph in the above solvent system, a second system of ethyl acetate/chloroform (2:1) was used. Chromatography with known aflatoxins provided identification of most metabolites. Unknown AFB₂ metabolites and regions of the chromatogram showing no fluorescence were demarcated in reference to the R_F of the standards. All portions of the chromatogram were scraped into vials for liquid scintillation counting. For each duplicate flask at each incubation time, 2 TLC plates were developed. AFB₂ and its chloroform-soluble metabolites were identified by their UV fluorescence on the silica gel plates.

Other Assays. The protein content of the PMS was

determined by the method of Lowry *et al.* (8). Microsomal enzymatic activity of the PMS was measured by the O-demethylation of *p*-nitroanisole (7). The UV fluorescence of the aflatoxins on the TLC plates was photographed with Kodachrome 25 film (Eastman Kodak Co., Rochester, N. Y.).

Calculations. Rates of AFB₂ metabolism and the quantity of the metabolites formed were calculated in relation to the weight of the whole-liver equivalent and as a function of the protein content of the PMS fraction. In the chloroform:acetone:water solvent system, AFB₂ and aflatoxicol cochromatograph; hence the amounts of these 2 aflatoxins present were determined by chromatography in the second solvent system (ethyl acetate:chloroform), in which they were satisfactorily resolved.

RESULTS

Total conversion of AFB₂ to all metabolites by liver preparations of 4 species is summarized in Chart 1. Data for duck and human liver preparations are from duplicate experiments, whereas only single experiments with rat and mouse livers were performed because replicate samples produced virtually identical values in preliminary experiments. AFB₂ at <7% was metabolized by rat, mouse, and human livers. Duck liver was capable of extensive metabolism, converting 40 to 60% of the substrate to metabolites.

Metabolites produced by the different liver preparations are summarized in Table 1. With respect to chloroform-soluble derivatives, livers of the mouse and of 1 human produced barely detectable amounts of substances with chromatographic and fluorescence properties expected for aflatoxins Q₂ and P₂, although these compounds were not specifically identified (11). All species except humans produced blue fluorescent compounds that migrated in the aflatoxin M₁ to M₂ aflatoxin region but that were also unidentified. Both samples of duck liver also produced compounds with chromatographic properties expected for aflatoxicols 1 and 2.

Duck liver preparations also produced a blue fluorescent metabolite with chromatographic properties of AFB₁. This metabolite was found to cochromatograph with authentic AFB₁ in the 2 TLC system described in "Materials and Methods" and also in a third solvent system, chloroform:methanol (19:1).




Chart 1. Total metabolism of AFB₂ by PMS preparations of mouse, rat, duck, and human livers. Each incubation mixture contained PMS equivalent to 0.2 g whole liver; each point represents the mean of 4 values (duplicate chromatograms of 2 incubation flasks; in all cases the S.D. < 6%).

Table 1
 AFB₂ metabolites after a 15-min incubation

The identity of metabolites is based on chromatographic properties analogous to metabolites produced from AFB₁ (11).

Aflatoxin fraction	nmol aflatoxin/mg protein/15 min					
	Duck 1	Duck 2	Rat	Mouse	Human 1	Human 2
B ₁	0.5 ± 0.0 ^a	0.2 ± 0.1	ND ^b	ND	ND	ND
Aflatoxicol 1	0.1 ± 0.1	ND	ND	ND	ND	ND
Aflatoxicol 2	0.5 ± 0.1	0.5 ± 0.1	ND	ND	ND	ND
Q ₂	ND	ND	ND	0.0 ± 0.1	0.3 ± 0.1	ND
P ₂	ND	ND	ND	0.0 ± 0.2	0.1 ± 0.1	ND
M ₁ or M region	0.3 ± 0.1	0.3 ± 0.1	0.0 ± 1.0	0.3 ± 0.4	ND	ND
M ₂	0.9 ± 0.1	0.4 ± 0.1	ND	ND	ND	ND
O+	0.4 ± 0.1	ND	ND	ND	ND	ND
Origin	0.3 ± 0.0	0.4 ± 0.2	0.0 ± 1.0	0.2 ± 0.2	0.2 ± 0.1	ND
Chloroform-insoluble	1.6 ± 0.3	0.8 ± 0.1	1.0 ± 1.0	0.0 ± 0.1	0.3 ± 0.1	0.0 ± 0.0
Total conversion	4.2 ± 0.2	3.4 ± 0.3	2.0 ± 0.2	0.8 ± 0.4	1.2 ± 0.2	2.0 ± 0.0

^a Mean ± S.D.

^b ND, none detected.

The kinetics of formation of this metabolite, presumed to be AFB₁, are shown in Chart 2. Both duck liver PMS preparations produced this derivative, which accumulated during the early portions of the incubation period. After 5 to 15 min, its concentration declined, possibly reflecting further metabolism of AFB₁ through pathways described previously (11).

As an independent indication of mixed-function oxygenase activity of the liver preparations, the activity of marker enzyme *p*-nitroanisole *O*-demethylase was measured. The activity of this enzyme for each species is summarized in Chart 3. Rat, mouse, and human livers showed greater activity than did duck liver, but all species clearly contained active mixed-function oxygenases.

DISCUSSION

The data in Chart 1 and Table 1 show that AFB₂ was metabolized only to a small extent by rat, mouse, and human liver preparations, but duck liver actively transformed this compound to a series of metabolites. Low levels of activity in the other preparations cannot be attributed to an overall lack of mixed-function oxygenase activity, since the preparations with lower capability for AFB₂ conversion had higher levels of the microsomal marker enzyme than had duck liver preparations.

Duck liver preparations metabolized AFB₂ differently than did those from rat, mouse, and human liver. In addition to more extensive overall metabolism, 2 to 8% of the AFB₂ was initially metabolized to a compound with chromatographic properties identical with AFB₁. For duck liver preparations the acute AFB₂ dose that killed 50% of the animals was more than 170 times less than AFB₁ dose (14). If duck liver synthesized AFB₁ from AFB₂ *in vivo* at rates comparable to its *in vitro* synthesis, the relationship between the doses that killed 50% of the animals for the compounds in duck liver could be explained. However, evidence for this metabolic pathway in rat, mouse, and human liver was not found in these experiments.

These findings are pertinent to elucidation of the mechanisms of action underlying aflatoxin carcinogenesis and




Chart 2. Formation of AFB₁ from AFB₂ by duck liver PMS equivalent to 0.2 g whole liver. Experimental conditions are the same as those described in Chart 1.

toxicity. Earlier experiments demonstrated that AFB₂ was weakly carcinogenic to rat liver; the effective dose was 150 times greater than that for AFB₁ (14, 15). The formation of small amounts of AFB₁ was suggested as a possible basis for the carcinogenicity of AFB₂. Direct evidence in support of that suggestion has recently been provided by Swenson *et al.* (12) who showed that AFB₂ forms nucleic acid adducts in the liver of rats dosed with the compound and, further, that aflatoxin B₁-2,3-oxide is an intermediate in the formation of those adducts, as indicated by their chromatographic identity to adducts formed from AFB₁. Transformation of AFB₂ to aflatoxin B₁-2,3-oxide would presumably occur through the intermediate formation of AFB₁ by desaturation at the 2,3-carbons of AFB₂. Interestingly, the ratio of nucleic acid adducts formed from the 2 compounds was very similar to the ratio of their carcinogenic potencies, approximately 1:100 (AFB₂:AFB₁).

It is difficult to compare quantitatively the metabolism of AFB₁ and AFB₂ by rat and mouse liver because so little total metabolism occurred in either case. However, some interesting structure-activity relationships based on *in vivo* ob-




Chart 3. Activity of microsomal marker enzyme *p*-nitroanisole *O*-demethylase in liver preparations used in experiments depicted in Charts 1 and 2. Experimental conditions are the same as those described in Chart 1.

servations are worth recounting. Edwards *et al.* (4) noted that rats dosed *i.p.* with [^{14}C]AFB₁ and [^{14}C]AFB₂ retained less AFB₂ than AFB₁ in the liver. AFB₁ also inhibited rat RNA polymerase, whereas, at 200 times the quantity of AFB₁, AFB₂ had no effect (5). In a microsomal-mediated system, AFB₂ was 100 times less toxic to bacteria (6); a similar relationship was found with respect to the mutagenicity of *Salmonella typhimurium* (16).

ACKNOWLEDGMENTS

The authors thank Dr. A. L. Demain (Department of Nutrition and Food Science, Massachusetts Institute of Technology, Cambridge, Mass.) and Dr. D. P. H. Hsieh (Department of Environmental Toxicology, University of California, Davis, Calif.) for the preparations of ^{14}C -labeled aflatoxins.

REFERENCES

- Büchi, G. H., Müller, P. M., Roebuck, B. D., and Wogan, G. N. Aflatoxin Q₁: A Major Metabolite of Aflatoxin B₁ Produced by Human Liver. *Res. Commun. Chem. Pathol. Pharmacol.*, **8**: 585-592, 1974.
- Carnaghan, R. B. A., Hartley, R. D., and O'Kelly, J. Toxicity and Fluorescence Properties of the Aflatoxins. *Nature*, **200**: 1101, 1963.
- Dalezios, J. I., Krieger, R. I., and Hsieh, D. P. H. The *in Vitro* Metabolism of Aflatoxin B₁ by Rhesus Monkey Liver. *Federation Proc.*, **31**, 733, 1972.
- Edwards, G. S., Wogan, G. N., Sporn, M. B., and Pong, R. S. Structure-Activity Relationships in DNA Binding and Nuclear Effects of Aflatoxins and Analogs. *Cancer Res.*, **31**: 1943-1950, 1971.
- Essigmann, J. M., Croy, R. G., Nadzan, A. M., Busby, W. F., Jr., Reinhold, V., Büchi, G., and Wogan, G. N. Structural Identification of the Major DNA Adduct Formed by Aflatoxin B₂ *in Vitro*. *Proc. Natl. Acad. Sci. U. S.*, **74**: 1870-1874, 1977.
- Garner, R. C., Miller, E. C., and Miller, J. A. Liver Microsomal Metabolism of Aflatoxin B₁ to a Reactive Derivative Toxic to *Salmonella typhimurium* TA 1530. *Cancer Res.*, **32**: 2058-2066, 1972.
- Kinoshita, F. K., Frawley, J. P., and DuBois, K. P. Quantitative Measurement of Induction of Hepatic Microsomal Enzymes by Various Dietary Levels of DDT and Toxaphene. *Toxicol. Appl. Pharmacol.*, **9**: 505-513, 1966.
- Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein Measurement with the Folin Phenol Reagent. *J. Biol. Chem.*, **193**: 265-275, 1951.
- Robertson, J. A., Pons, W. A., Jr., and Goldblatt, L. A. Preparation of Aflatoxins and Determinations of Their Ultraviolet and Fluorescent Characteristics. *J. Agr. Food Chem.*, **15**: 798-801, 1967.
- Roebuck, B. D., and Siegel, W. G. *In Vitro* Metabolism of Aflatoxins B₁ and B₂: Species Comparison. *Am. Assoc. Cancer Res.*, **16**: 94, 1975.
- Roebuck, B. D., and Wogan, G. N. Species Comparison of *in Vitro* Metabolism of Aflatoxin B₁. *Cancer Res.*, **37**: 1649-1656, 1977.
- Swenson, D. H., Lin, J.-K., Miller, E. C., and Miller, J. A. Aflatoxin B₁-2,3-oxide as a Probable Intermediate in the Covalent Binding of Aflatoxins B₁ and B₂ to Rat Liver DNA and Ribosomal RNA *in vivo*. *Cancer Res.*, **37**: 172-181, 1977.
- Wogan, G. N. Aflatoxin Carcinogenesis. *Methods Cancer Res.*, **7**: 309-344, 1973.
- Wogan, G. N., Edwards, G. S., and Newberne, P. M. Structure-Activity Relationships in Toxicity and Carcinogenicity of Aflatoxins and Analogs. *Cancer Res.*, **31**: 1936-1942, 1971.
- Wogan, G. N., and Newberne, P. M. Dose-Response Characteristics of Aflatoxin B₁ Carcinogenesis in the Rat. *Cancer Res.*, **27**: 2370-2376, 1967.
- Wong, J. J., and Hsieh, D. P. Mutagenicity of Aflatoxins Related to Their Metabolism and Carcinogenic Potential. *Proc. Natl. Acad. Sci. U. S.*, **73**: 2241-2244, 1976.

Cancer Research

The Journal of Cancer Research (1916–1930) | The American Journal of Cancer (1931–1940)

In Vitro Metabolism of Aflatoxin B₂ by Animal and Human Liver

Bill D. Roebuck, Wayne G. Siegel and Gerald N. Wogan

Cancer Res 1978;38:999-1002.

Updated version Access the most recent version of this article at:
<http://cancerres.aacrjournals.org/content/38/4/999>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://cancerres.aacrjournals.org/content/38/4/999>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.